Entrada Therapeutics, Inc. logo TRDA - Entrada Therapeutics, Inc.

NEXT EARNINGS: Feb 26, 2026 (in 1 day) EPS Est: $-1.32 | Rev Est: $7.4M
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 4
HOLD 1
SELL 0
STRONG
SELL
0
| PRICE TARGET: $18.00 DETAILS
HIGH: $21.00
LOW: $13.00
MEDIAN: $20.00
CONSENSUS: $18.00
UPSIDE: 56.79%
Market Cap: 438.76M
Volume: 140,222
Avg Volume: 208,540
52 Week Range: 4.93-13.82
Sector: Healthcare
Industry: Biotechnology
Beta: -0.12
Last Dividend: $N/A
Exchange: NASDAQ
Country: US
Employees: 183
IPO Date: 2021-10-29
EPS (TTM): 1.76
P/E Ratio: 9.83
Revenue (TTM): 210.78M
Total Assets: 526.32M
Total Debt: 59.21M
Cash & Equiv: 101.21M
Rev Growth (5Y): 63.4%
EPS Growth (5Y): N/A
FCF Growth (5Y): N/A
ROCE: 9.7%
Debt/Equity: 0.14

Earnings History

Date EPS Actual EPS Est EPS Surprise Rev Actual Rev Est Rev Surprise
2025-11-06 $-1.06 $-1.04 -1.9% $1.6M $8.5M -81.0%
2025-08-06 $-1.04 $-0.86 -20.9% $1.9M $7.8M -75.1%
2025-05-08 $-0.42 $-0.78 +46.2% $20.6M $9.8M +110.4%
2025-02-27 $0.03 $-0.66 +104.5% $37.4M $13.1M +185.0%
2024-11-05 $-0.35 $-0.67 +47.8% $19.6M $12.9M +51.4%
2024-08-13 $1.55 $0.14 +1007.1% $94.7M $12.3M +668.6%
2024-05-07 $0.68 $-0.59 +215.3% $59.1M $15.0M +294.7%
2024-03-13 $-0.29 $-0.07 -314.3% $41.8M $23.7M +76.6%

Track Record

Statements >
Metric 2024 2023 2022 2021 2020 2019
Revenue 210.78M 129.01M 0 0 0 0
Net Income 65.63M (6.68M) (94.62M) (51.16M) (26.52M) (4.65M)
EPS 1.76 -0.20 -2.79 -1.60 -0.84 -4.44
Total Assets 526.32M 469.19M 252.06M 305.83M 43.53M 18.24M
Total Debt 59.21M 68.23M 25.94M 0 0 0
Cash & Equivalents 101.21M 67.60M 45.16M 291.06M 39.05M 16.84M
Operating Cash Flow (41.56M) 139.80M (93.79M) (50.86M) (25.57M) (10.80M)
Free Cash Flow (44.72M) 134.19M (96.67M) (55.44M) (27.89M) (11.43M)
FCF per Share -1.20 4.06 -3.09 -1.78 -0.89 -10.91
Book Value 428.68M 242.36M 212.55M 298.72M (41.49M) (15.52M)
Cash & ST Investments 420.00M 351.97M 188.71M 291.06M 39.05M 16.84M
ROC Equity 0.15 -0.03 -0.45 -0.17 N/A N/A